drugset / Trial / NCT01646034
High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study investigates the effect of high-dose alkylating chemotherapy compared with standard chemotherapy as part of a multimodality treatment approach in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency.
Timeline
- Start
- 2014-09
- Primary completion
- 2023-01
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 800 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 3000 mg/m2 | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Subject | Thiotepa | Other / unclassified | 240 mg/m2 | — |